Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
Masakazu Toi; Shigeru Imoto; Takanori Ishida; Yoshinori Ito; Hiroji Iwata; Norikazu Masuda; Hirofumi Mukai; Shigehira Saji; Akira Shimizu; Takafumi Ikeda; Hironori Haga; Toshiaki Saeki; Kenjiro Aogi; Tomoharu Sugie; Takayuki Ueno; Takayuki Kinoshita; Yuichiro Kai; Masahiro Kitada; Yasuyuki Sato; Kenjiro Jimbo; Nobuaki Sato; Hiroshi Ishiguro; Masahiro Takada; Yasuo Ohashi; Shinji Ohno
The Lancet Oncology, Jan. 2021